Abstract
Several drugs are now available for the treatment and prevention of Pneumocystis carinii pneumonia. These include trimethoprim-sulfamethoxazole and pentamidine isethionate as first-line drugs and dapsone-trimethoprim, trimetrexate, piritrexim, fansidar, difluoromethylornithine, and clindamycin plus primaquine as drugs in later stages of clinical development. A hydroxynaphthoquinone, called 566C80, offers promise in preclinical studies. The use of corticosteroids in the supportive management of P. carinii pneumonitis is undergoing clinical study.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 287-295 |
| Number of pages | 9 |
| Journal | Annual review of medicine |
| Volume | 42 |
| DOIs | |
| State | Published - 1991 |
| Externally published | Yes |
Keywords
- Immunocompromised host
- Pentamidine
- Trimethoprim-sulfamethoxazole
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)